Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients

NCT06918834 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

236

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

OTHER: Immediate HSCT Group
OTHER: Bridging Therapy Group

Sponsor

Institute of Hematology & Blood Diseases Hospital, China